Clinical Trial Update: Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This update reports the termination of a phase 1/2 trial evaluating cabozantinib in combination with pembrolizumab for advanced metastatic melanoma, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cabometyx (cabozantinib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: John Rieth | Conditions: Advanced Metastatic Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-24